WO2010143803A3 - New nicotinamide derivatives with anti-androgen effects, processes of preparing, and antiandrogens comprising the same - Google Patents

New nicotinamide derivatives with anti-androgen effects, processes of preparing, and antiandrogens comprising the same Download PDF

Info

Publication number
WO2010143803A3
WO2010143803A3 PCT/KR2010/000960 KR2010000960W WO2010143803A3 WO 2010143803 A3 WO2010143803 A3 WO 2010143803A3 KR 2010000960 W KR2010000960 W KR 2010000960W WO 2010143803 A3 WO2010143803 A3 WO 2010143803A3
Authority
WO
WIPO (PCT)
Prior art keywords
same
antiandrogens
nicotinamide derivatives
androgen
preparing
Prior art date
Application number
PCT/KR2010/000960
Other languages
French (fr)
Other versions
WO2010143803A2 (en
Inventor
Keesook Lee
Chin-Hee Song
Won-Jea Cho
Original Assignee
Industry Foundation Of Chonnam National University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from KR1020090069557A external-priority patent/KR101103503B1/en
Application filed by Industry Foundation Of Chonnam National University filed Critical Industry Foundation Of Chonnam National University
Publication of WO2010143803A2 publication Critical patent/WO2010143803A2/en
Publication of WO2010143803A3 publication Critical patent/WO2010143803A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/28—Antiandrogens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C07D213/82—Amides; Imides in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)

Abstract

Provided are novel nicotinamide derivatives and pharmaceutically acceptable salts thereof with anti-androgen effects, preparing processes of the same and antiandrogens containing the same as active ingredients. More particularly, the said nicotinamide derivatives have anti-androgen activity, so that they can be effectively used as a preventive or therapeutic agent for androgen-related diseases such as prostatic disease, androgenic alopecia and acne.
PCT/KR2010/000960 2009-06-08 2010-02-17 New nicotinamide derivatives with anti-androgen effects, processes of preparing, and antiandrogens comprising the same WO2010143803A2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
KR20090050320 2009-06-08
KR10-2009-0050320 2009-06-08
KR1020090069557A KR101103503B1 (en) 2009-06-08 2009-07-29 New nicotinamide derivatives with anti-androgen effect, process for preparing and anti-androgens comprising the same
KR10-2009-0069557 2009-07-29

Publications (2)

Publication Number Publication Date
WO2010143803A2 WO2010143803A2 (en) 2010-12-16
WO2010143803A3 true WO2010143803A3 (en) 2011-01-27

Family

ID=43309310

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2010/000960 WO2010143803A2 (en) 2009-06-08 2010-02-17 New nicotinamide derivatives with anti-androgen effects, processes of preparing, and antiandrogens comprising the same

Country Status (1)

Country Link
WO (1) WO2010143803A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2982261B1 (en) 2011-11-04 2014-06-13 Galderma Res & Dev NOVEL AMIDES, AND THEIR PHARMACEUTICAL OR COSMETIC USE
US9682960B2 (en) 2013-12-19 2017-06-20 Endorecherche, Inc. Non-steroidal antiandrogens and selective androgen receptor modulators with a pyridyl moiety
WO2023119230A1 (en) 2021-12-22 2023-06-29 L'oreal Coagulation pathway and nicotinamide-adenine dinucleotide pathway modulating compositions and methods of their use

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030050325A1 (en) * 1997-09-05 2003-03-13 Bruno Bernard Novel compounds of the indolecarboxylic family and use thereof
WO2003082853A1 (en) * 2002-03-28 2003-10-09 Astrazeneca Ab New compounds
US20060025426A1 (en) * 2002-12-11 2006-02-02 Fraley Mark E Tyrosine kinase inhibitors
US20060111355A1 (en) * 2004-11-23 2006-05-25 Wyeth Gonadotropin releasing hormone receptor antagonists
WO2007061880A1 (en) * 2005-11-23 2007-05-31 Merck & Co., Inc. Spirocyclic compounds as hdac inhibitors
US20080221157A1 (en) * 2004-07-12 2008-09-11 Istituto Di Ricerche Di Biologia Molecolare P Ange Amide Derivatives as Inhibitors of Histone Deacetylase
US20090105264A1 (en) * 2005-11-03 2009-04-23 Christopher Hamblett Substituted Nicotinamide Compounds

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030050325A1 (en) * 1997-09-05 2003-03-13 Bruno Bernard Novel compounds of the indolecarboxylic family and use thereof
WO2003082853A1 (en) * 2002-03-28 2003-10-09 Astrazeneca Ab New compounds
US20060025426A1 (en) * 2002-12-11 2006-02-02 Fraley Mark E Tyrosine kinase inhibitors
US20080221157A1 (en) * 2004-07-12 2008-09-11 Istituto Di Ricerche Di Biologia Molecolare P Ange Amide Derivatives as Inhibitors of Histone Deacetylase
US20060111355A1 (en) * 2004-11-23 2006-05-25 Wyeth Gonadotropin releasing hormone receptor antagonists
US20090105264A1 (en) * 2005-11-03 2009-04-23 Christopher Hamblett Substituted Nicotinamide Compounds
WO2007061880A1 (en) * 2005-11-23 2007-05-31 Merck & Co., Inc. Spirocyclic compounds as hdac inhibitors

Also Published As

Publication number Publication date
WO2010143803A2 (en) 2010-12-16

Similar Documents

Publication Publication Date Title
WO2010088000A3 (en) Antifibrotic compounds and uses thereof
MX2013002584A (en) Pyrazoloquinoline compound.
MX341531B (en) Sgc stimulators.
TN2012000428A1 (en) Bisaryl-bonded aryltriazolones and use thereof
WO2007101864A3 (en) Compounds that modulate ppar activity, their preparation and use
WO2010127152A3 (en) Compounds and compositions as microsomal prostaglandin e synthase-1 inhibitors
CA2818925A1 (en) Inhibitors of the activity of complex iii of the mitochondrial electron transport chain and use thereof for treating diseases
MX2012000414A (en) Pyridin-4-yl derivatives.
WO2008148074A3 (en) Inhibitors of mtor and methods of treatment using same
WO2011127070A3 (en) IRE-1α INHIBITORS
WO2010088450A3 (en) Arylamide derivatives useful in the treatment of diseases associated with serca activity
WO2011056021A3 (en) Use of benzo-heterocycle derivatives for preventing and treating cancer or for inhibiting cancer metastasis
WO2011021892A3 (en) Composition for skin improvement comprising hexamidines and retinoids
WO2011153192A3 (en) Cytochrome p450 inhibitors and uses thereof
JO3052B1 (en) Dividable galenical form allowing modified release of the active ingredient
MX344109B (en) Meglumine salt formulations of 1-(5,6-dichloro-1h-benzo[d]imidazo l-2-yl)-1h-pyrazole-4-carboxylic acid.
TN2012000279A1 (en) Processes for the manufacture of a pharmaceutically active agent
TN2012000092A1 (en) Therapeutic agent for mood disorders
WO2009041663A1 (en) Agent for prevention and/or treatment of skin diseases
WO2011042902A3 (en) Microcapsules comprising benzoyl peroxide and topical compositions comprising them
WO2012118308A3 (en) Composition for preventing and treating cardiovascular diseases, containing pyrazole derivative
WO2011088160A3 (en) Novel cyp17 inhibitors
WO2010062506A3 (en) Decahydro-1h-indenoquinolinone and decahydro-3h-cyclopentaphenanthridinone cyp17 inhibitors
WO2013019091A3 (en) A COMPOUND FOR INHIBITING 11β-HYDROXY STEROID DEHYDROGENASE 1, AND A PHARMACEUTICAL COMPOSITION COMPRISING THE SAME
WO2010143803A3 (en) New nicotinamide derivatives with anti-androgen effects, processes of preparing, and antiandrogens comprising the same

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10786286

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 10786286

Country of ref document: EP

Kind code of ref document: A2